Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer

• US 20060078533A1
• Filed: 11/08/2005
• Published: 04/13/2006
• Est. Priority Date: 10/12/2004
• Status: Abandoned Application

• Current Assignee: Osemwota Sota Omoigui
• Original Assignee: Osemwota Sota Omoigui
• Inventors: Omoigui, Osemwota Sota
• Application Number:
  US11/268,609
• Publication Number:
  US 20060078533A1
• Time in Patent Office: Days
• US Class Current: 424/78.140
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 36/00 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines antigens from pollen A61K39/36
• CPC Class Codes: A61K 36/062 Ascomycota
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61K 36/31 Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• CPC Class Codes: A61K 36/48 Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• CPC Class Codes: A61K 36/63 Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• CPC Class Codes: A61K 36/82 Theaceae (Tea family), e.g. camellia
• CPC Class Codes: A61K 36/899 Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• CPC Class Codes: A61K 38/553 Renin inhibitors
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07K 16/248 IL-6

Abstract

This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway.

Claims

1. A method of prevention and treatment of aging and age-related disorders by synergistic inhibition or reduction of Interleukin-6 mediated inflammation in a human or other animal subject. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR gamma and/or PPAR beta/delta activators/ligands or a functional fragment thereof. Said method comprises administering, to said subject, separately, sequentially or simultaneously, any one of the following combinations of components that are inhibitors of interleukin-6 mediated inflammation;

I. A and B

II. A, B, and C

III. A and C

IV. B and C

Wherein

A is an inhibitor of cholesterol synthesis and includes one or several Statins and Bisphosphonates selected from the Statin group including of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, red yeast rice, red yeast grain, red yeast powder, fermentation products of filamentous fungi, including Monascus, Aspergillus, Penicillium, Pleurotus, Pythium, Hypomyces, Paelicilomyces, Eupenicillium, and Doratomycesmonakolin K, monakolin L, monakolin J, monakolin X, monakolin M, compactin (ML-236B), ML-236-A, and NL-236C and other statins or a pharmaceutically acceptable salt thereof and the Bisphosphonate group including of Pamidronate, Etidronate, Clodronate, Alendronate, phosphonic acid derivatives, an ester thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof

B is one or several inhibitors or antibodies of the Interleukin-6 (IL-6) signal transduction pathway including interleukin-6 inhibitor or antibody, interleukin-6 receptor inhibitor or antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors or antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR alpha, PPAR gamma and/or PPAR beta/delta activators/ligands or a functional fragment thereof selected from synthetic or plant derived polyphenolic compounds including phenolic acids, flavonoids, stilbenes, lignans, Anthocyanidins (e.g., cyanidin, pelargonidin);

Flavanols (e.g., epicatechin, gallocatechin);

Flavones (e.g., apigenin, luteolin);

Flavonols (e.g., kaempferol, myricetin, quercetin);

Flavanones (e.g., hesperidin, naringenin);

Isoflavones (e.g., genistein, daidzein, biochanin), Proanthocyanidins, catechin, epicatechin, and their gallic acid esters, Prodelphinidins, gallocatechin, epigallocatechin, and their gallic acid esters as the monomeric units, soy protein material and/or isoflavones selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, soy beans, chick peas, ground nuts, lentils and various other types of beans and peas, soy-based food products manufactured from whole soybeans such as tofu, soynuts, soy milk, soy cheese, and soy yoghurt, soy-based food products manufactured in part using soybean-derived protein ingredients such as soy flour, ST flour, ISP, and SPC, Cocoa polyphenols extracted from cocoa beans and derivatives thereof including fresh beans, defatted solids, comminuted trash beans, cocoa powder, low-fat cocoa powder, cocoa shells, cocoa waste, Polyphenols found in nuts, nut skin extracts, tea and tea derivatives, (e.g., Camelliasinensis, C. assamica), coffee beans (Coffeaarabica, C. aniphora, C. robusta, C. liberica) and derivatives thereof, polyphenols of vegetables and fruits including pineapple, wax apple, rambutan, lichi, guava, and mango, mangiferin and polyphenols derived from fruits, vegetables, cereals, dry legumes, chocolate, and beverages, such as grape juice tea, coffee, or wine.

C. is a cholesterol lowering agent or technique selected from the group including of (i) low cholesterol or low fat, high fiber, fruit, nuts, cereal, grains, legume and/or vegetable diet/diet supplement (ii) sequestrants (cholestyramine, colestipol and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPAR alpha agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (v) inhibitors of cholesterol absorption selected from the group of phytosterols including alpha sitosterol, beta sitosterol, stigmasterol, ergosterol, campesterol, alpha sitostanol, beta sitostanol, campestanol, oryzanol and brassiciasterol, their fatty acid esters, and the like, food products containg phytosterols including rice bran, corn bran, corn germ, wheat germ oil, corn oil, safflower oil, oat oil, olive oil, cotton seed oil, soybean oil, e.g., soybean oil distillates, peanut oil, black tea, orange juice, valencia, green tea, Colocsia, kale, broccoli, sesame seeds, shea oils, grapeseed oil, rapeseed oil, linseed oil, canola oil, tall oil from wood pulp and other resinous oil from wood pulp and ACAT ACAT (acyl CoA;

cholesterol acyltransferase) inhibitors for example melinamide and (vi) probucol, an ester thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof.

said components being administered separately, sequentially or simultaneously, in amounts which have the effect of ameliorating the vascular and age-related disorders.

2. The method of claim 1, wherein;

a) said aging and age-related disorder is atherosclerosis.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route

3. The method of claim 1, wherein;

a) said aging and age-related disorder is peripheral vascular disease.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route

4. The method of claim 1, wherein;

a) said aging and age-related disorder is coronary artery disease.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route

5. The method of claim 1, wherein;

a) said aging and age-related disorder is osteoporosis.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

6. The method of claim 1, wherein;

a) said aging and age-related disorder is arthritis.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

7. The method of claim 1, wherein;

a) said aging and age-related disorder is Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance or insulin resistance.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

8. The method of claim 1, wherein;

a) said aging and age-related disorder is obesity

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

9. The method of claim 1, wherein;

a) said aging and age-related disorder is hypertension

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

10. The method of claim 1, wherein;

a) said aging and age-related disorder is dementia

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

11. The method of claim 1, wherein;

a) said aging and age-related disorder is Alzheimer'"'"'s disease

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

12. The method of claim 1, wherein;

a) said aging and age-related disorder is Aging

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

13. The method of claim 1, wherein;

a) said aging and age-related disorder is Periodontal disease or other chronic low grade infection such as Chlamydia pneumoniae

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

14. The method of claim 1, wherein;

a) said aging and age-related disorder is primary or secondary cancers or tumors including but not limited to adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer and thyroid cancer.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

15. A method of prevention and treatment of aging and age-related disorders by inhibition or reduction of Interleukin-6 mediated inflammation in a human or other animal subject through regulation of cholesterol metabolism and isoprenoid depletion, or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR alpha, or a functional fragment thereof. Said method comprises administering, to said subject, separately, sequentially or simultaneously, in amounts which have the effect of ameliorating the vascular and age-related disorders, one or several inhibitors or antibodies of the Interleukin-6 (IL-6) signal transduction pathway selected from synthetic or plant derived polyphenolic compounds including phenolic acids, flavonoids, stilbenes, lignans, Anthocyanidins (e.g., cyanidin, pelargonidin);

Flavanols (e.g., epicatechin, gallocatechin);

Flavones (e.g., apigenin, luteolin);

Flavonols (e.g., kaempferol, myricetin, quercetin);

Flavanones (e.g., hesperidin, naringenin);

Isoflavones (e.g., genistein, daidzein, biochanin), Proanthocyanidins, catechin, epicatechin, and their gallic acid esters, Prodelphinidins, gallocatechin, epigallocatechin, and their gallic acid esters as the monomeric units, soy protein material and/or isoflavones selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, soy beans, chick peas, ground nuts, lentils and various other types of beans and peas, soy-based food products manufactured from whole soybeans such as tofu, soynuts, soy milk, soy cheese, and soy yoghurt, soy-based food products manufactured in part using soybean-derived protein ingredients such as soy flour, ST flour, ISP, and SPC, Cocoa polyphenols extracted from cocoa beans and derivatives thereof including fresh beans, defatted solids, comminuted trash beans, cocoa powder, low-fat cocoa powder, cocoa shells, cocoa waste, Polyphenols found in nuts, nut skin extracts, tea and tea derivatives, (e.g., Camelliasinensis, C. assamica), coffee beans (Coffeaarabica, C. aniphora, C. robusta, C. liberica) and derivatives thereof, polyphenols of vegetables and fruits including pineapple, wax apple, rambutan, lichi, guava, and mango, mangiferin and polyphenols derived from fruits, vegetables, cereals, dry legumes, chocolate, and beverages, such as grape juice tea, coffee, or wine.

16. The method of claim 15, wherein;

a) said aging and age-related disorder is peripheral vascular disease.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

17. The method of claim 15, wherein;

a) said aging and age-related disorder is coronary artery disease.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

18. The method of claim 15, wherein;

a) said aging and age-related disorder is arthritis.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

19. The method of claim 15, wherein;

a) said aging and age-related disorder is Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance or insulin resistance.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

20. The method of claim 15, wherein;

a) said aging and age-related disorder is obesity

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

21. The method of claim 15, wherein;

a) said aging and age-related disorder is hypertension

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

22. The method of claim 15, wherein;

a) said aging and age-related disorder is dementia

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

23. The method of claim 15, wherein;

a) said aging and age-related disorder is Alzheimer'"'"'s disease

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

24. The method of claim 15, wherein;

a) said aging and age-related disorder is Aging

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

25. The method of claim 15, wherein;

a) said aging and age-related disorder is Periodontal disease or other chronic low grade infection such as Chlamydia pneumoniae

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

26. The method of claim 15, wherein;

a) said aging and age-related disorder is primary or secondary cancers or tumors including but not limited to adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer and thyroid cancer.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

27. A method of prevention and treatment of aging and age-related disorders by inhibition or reduction of Interleukin-6 mediated inflammation in a human or other animal subject through regulation of cholesterol metabolism and isoprenoid depletion, or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR gamma and/or PPAR beta/delta activators/ligands or a functional fragment thereof. in a human or other animal subject. Said method comprises administering, to said subject, in amounts which have the effect of ameliorating the aging and age-related disorders, a HMG-CoA reductase inhibitor selected from the group including of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, red yeast rice, red yeast grain, red yeast powder and other statins or a pharmaceutically acceptable salt thereof.

28. The method of claim 27, wherein;

a) said aging and age-related disorder is peripheral vascular disease.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

29. The method of claim 27, wherein;

a) said aging and age-related disorder is coronary artery disease.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

30. The method of claim 27, wherein;

a) said aging and age-related disorder is arthritis.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

31. The method of claim 27, wherein;

a) said aging and age-related disorder is Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance or insulin resistance.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

32. The method of claim 27, wherein;

a) said aging and age-related disorder is obesity

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

33. The method of claim 27, wherein;

a) said aging and age-related disorder is hypertension

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

34. The method of claim 27, wherein;

a) said aging and age-related disorder is dementia

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

35. The method of claim 27, wherein;

a) said aging and age-related disorder is Alzheimer'"'"'s disease

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

36. The method of claim 27, wherein;

a) said aging and age-related disorder is Aging

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

37. The method of claim 27, wherein;

a) said aging and age-related disorder is Periodontal disease or other chronic low grade infection such as Chlamydia pneumoniae

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

38. The method of claim 27, wherein;

a) said aging and age-related disorder is primary or secondary cancers or tumors including but not limited to adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer and thyroid cancer.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

39. A method of prevention and treatment of aging and age-related disorders by inhibition or reduction of Interleukin-6 mediated inflammation in a human or other animal subject. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR alpha, or a functional fragment thereof. Said method comprises administering simultaneously, sequentially or separately, to said subject, in amounts which have the effect of ameliorating the aging and age-related disorders, a bisphosphonate selected from the group including of Pamidronate, Etidronate, Clodronate, Alendronate, phosphonic acid derivatives, an ester thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof.

40. The method of claim 39, wherein;

a) said aging and age-related disorder is peripheral vascular disease.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

41. The method of claim 39, wherein;

a) said aging and age-related disorder is coronary artery disease.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

42. The method of claim 39, wherein;

a) said aging and age-related disorder is arthritis.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

43. The method of claim 39, wherein;

a) said aging and age-related disorder is Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance or insulin resistance.

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

44. The method of claim 39, wherein;

a) said aging and age-related disorder is obesity

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

45. The method of claim 39, wherein;

a) said aging and age-related disorder is hypertension

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

46. The method of claim 39, wherein;

a) said aging and age-related disorder is dementia

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

47. The method of claim 39, wherein;

a) said aging and age-related disorder is Alzheimer'"'"'s disease

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

48. The method of claim 39, wherein;

a) said aging and age-related disorder is Aging

b) a therapeutically effective amount of said regulator of cholesterol metabolism and interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

49. The method of claim 39, wherein;

a) said aging and age-related disorder is Periodontal disease or other chronic low grade infection such as Chlamydia pneumoniae

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

50. The method of claim 39, wherein;

a) said aging and age-related disorder is primary or secondary cancers or tumors including but not limited to adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer and thyroid cancer.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

51. A method of prevention and treatment of aging and age-related disorders by inhibition or reduction of Interleukin-6 mediated inflammation in a human or other animal subject. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleulin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR gamma and/or PPAR beta/delta activators/ligands or a functional fragment thereof. Said method comprises administering, to said subject, simultaneously, sequentially or separately, in amounts which have the effect of ameliorating the vascular and age-related disorders, a cholesterol lowering agent or technique selected from the group including of (i) low cholesterol or low fat diet (ii) sequestrants (cholestyramine, colestipol and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPAR.alpha agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (v) inhibitors of cholesterol absorption for example beta-sitosterol and ACAT (acyl CoA;

cholesterol acyltransferase) inhibitors for example melinamide and (vi) probucol, an ester thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof.

52. The method of claim 51, wherein;

a) said aging and age-related disorder is peripheral vascular disease.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

53. The method of claim 51, wherein;

a) said aging and age-related disorder is coronary artery disease.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

54. The method of claim 51, wherein;

a) said aging and age-related disorder is arthritis.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

55. The method of claim 51, wherein;

a) said aging and age-related disorder is Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance or insulin resistance.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

56. The method of claim 51, wherein;

a) said aging and age-related disorder is obesity

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

57. The method of claim 51, wherein;

a) said aging and age-related disorder is hypertension

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

58. The method of claim 51, wherein;

a) said aging and age-related disorder is dementia

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

59. The method of claim 51, wherein;

a) said aging and age-related disorder is Alzheimer'"'"'s disease

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

60. The method of claim 51, wherein;

a) said aging and age-related disorder is Aging

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

61. The method of claim 51, wherein;

a) said aging and age-related disorder is Periodontal disease or other chronic low grade infection such as Chlamydia pneumoniae

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

62. The method of claim 51, wherein;

a) said aging and age-related disorder is primary or secondary cancers or tumors including but not limited to adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer and thyroid cancer.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

63. A method of prevention and treatment of aging and age-related disorders by inhibition or reduction of Interleukin-6 mediated inflammation in a human or other animal subject. Said method comprises administering, to said subject, separately, sequentially or simultaneously, in amounts which have the effect of ameliorating the vascular and age-related disorders, one or several inhibitors or antibodies of the Interleukin-6 (IL-6) signal transduction pathway including interleukin-6 inhibitor or antibody, interleukin-6 receptor inhibitor or antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor κ

B (NF-κ

B) inhibitors/antibodies, Iκ

B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR alpha, PPAR gamma and/or PPAR beta/delta activators/ligands or a functional fragment thereof

64. The method of claim 63, wherein;

a) said aging and age-related disorder is peripheral vascular disease.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

65. The method of claim 63, wherein;

a) said aging and age-related disorder is coronary artery disease.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

66. The method of claim 63, wherein;

a) said aging and age-related disorder is arthritis.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

67. The method of claim 63, wherein;

a) said aging and age-related disorder is Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance or insulin resistance.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

68. The method of claim 63, wherein;

a) said aging and age-related disorder is obesity

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

69. The method of claim 63, wherein;

a) said aging and age-related disorder is hypertension

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

70. The method of claim 63, wherein;

a) said aging and age-related disorder is dementia

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

71. The method of claim 63, wherein;

a) said aging and age-related disorder is Alzheimer'"'"'s disease

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

72. The method of claim 63, wherein;

a) said aging and age-related disorder is Aging

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

73. The method of claim 63, wherein;

a) said aging and age-related disorder is Periodontal disease or other chronic low grade infection such as Chlamydia pneumoniae

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.

74. The method of claim 63, wherein;

a) said aging and age-related disorder is primary or secondary cancers or tumors including but not limited to adrenal cancer, astrocytoma, basal or squamous cell carcinoma, brain cancer, bladder cancer, breast cancer, colorectal cancer, chrondrosarcoma, cervical cancer, choriocarcinoma, esophageal cancer, endometrial carcinoma, erythroleukemia, Ewing'"'"'s sarcoma, gastrointestinal cancer, gliobastoma, glioma, head and neck cancer, hepatocellular carcinoma, hepatoma, leiomyoma, leukemia, melanoma, multiple myeloma, neural cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, testicular cancer and thyroid cancer.

b) a therapeutically effective amount of said component or combination of inhibitors of interleukin-6 mediated inflammation is administered subcutaneously, intramuscularly, intravenously, orally, rectally or by the sublingual, transmucosal, inhalational or transdermal route.